Business Overview: Century Therapeutics, Inc. (NASDAQ: IPSC)

---

Executive Summary

Century Therapeutics, Inc. is a Philadelphia-based, clinical-stage biotechnology company developing allogeneic, induced pluripotent stem cell (iPSC)-derived cell therapies — engineered "off-the-shelf" immune cell products designed to be manufactured in advance from a single master cell line, rather than from each individual patient's own cells as with conventional CAR-T therapy.

Century has no approved products and generates no commercial product revenue. Its importance to the iPSC/allogeneic cell therapy field comes from its proprietary Allo-Evasion™ immune-evasion technology and its ability to differentiate iPSCs into multiple therapeutically relevant cell types — natural killer (NK) cells, T cells, and insulin-producing beta islet cells — from the same engineered starting material, aimed at both autoimmune disease and cancer. The company's lead clinical program, CNTY-101, is being studied in an investigator-sponsored trial in lupus and related autoimmune diseases, while CNTY-813, a beta-islet-cell therapy for type 1 diabetes, is the company's current top development priority heading toward an IND filing.

---

1. Core Business Model & How They Work

As a clinical-stage biotech, Century does not yet sell products; it funds operations through cash reserves, equity financing, and (historically) upfront and milestone payments from pharmaceutical collaborators, while advancing its pipeline toward regulatory approval.

[ Engineered iPSC Master Cell Line ] ➡️ [ Allo-Evasion™ Gene Editing (Immune Evasion) ] ➡️ [ Differentiation into iNK / iT / Beta Islet Cells ] ➡️ [ In-House cGMP Manufacturing (Branchburg, NJ) ] ➡️ [ Clinical Trials ] ➡️ [ (Future) Regulatory Approval & Commercialization ]

Key Operational Drivers

1. Allogeneic, "Off-the-Shelf" Platform: Unlike autologous CAR-T therapies that must be manufactured individually for each patient, Century's iPSC-derived cells are produced in advance from a renewable master cell line, intended to enable faster treatment, lower per-patient manufacturing cost at scale, and repeat dosing.
2. Allo-Evasion™ Technology: Proprietary multi-locus gene editing intended to help transplanted cells evade immune rejection, a central technical challenge for any allogeneic cell therapy and a focus of Century's engineering efforts.
3. In-House Manufacturing: Century operates a 53,000-square-foot manufacturing facility in Branchburg, New Jersey (operational since 2022), which produced clinical supply for its CNTY-101 trials and received an EU Qualified Person declaration in February 2025, supporting future European clinical use.
4. Licensing and Collaboration Dependence: Century relies on licensed iPSC and reprogramming technology from Fujifilm Cellular Dynamics (FCDI), iCELL Inc., and Catalent Düsseldorf (the latter acquired via its purchase of Clade Therapeutics), and has historically relied on pharma partners for non-dilutive funding — most notably a terminated collaboration with Bristol Myers Squibb.

---

2. Product Portfolio / Pipeline

---

3. Competitive Landscape

Century competes in the crowded, well-funded cell-therapy field against both allogeneic-focused biotechs and large pharmaceutical companies developing their own cell and immunotherapy approaches.

• Allogeneic/iPSC-Focused Peers: Fate Therapeutics, Allogene Therapeutics, Caribou Biosciences, Nkarta Therapeutics, and Artiva Biotherapeutics are each pursuing off-the-shelf allogeneic cell therapies (iPSC-derived or otherwise) for cancer and/or autoimmune disease, competing directly with Century's core thesis.
• Autologous and Antibody-Based Standard of Care: Approved autologous CAR-T therapies, cadaveric islet transplantation, and existing biologics (e.g., teplizumab for T1D, anifrolumab and rituximab for autoimmune/B-cell disease) represent the current standard of care Century's pipeline must eventually outperform or meaningfully differentiate from.
• Large Pharma: Companies including Bristol Myers Squibb, a former Century collaborator turned potential competitor, continue to develop their own cell and immunotherapy programs with far greater capital resources.

---

4. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• Multi-Cell-Type Platform: The ability to differentiate the same engineered iPSC line into NK cells, T cells, or beta islet cells lets Century address autoimmune disease, oncology, and diabetes from one core technology base rather than building separate platforms.
• Allo-Evasion™ IP: Proprietary immune-evasion gene editing is central to making allogeneic cell therapy viable and is a meaningful technical and IP barrier versus less-engineered competitors.
• Owned Manufacturing: In-house cGMP manufacturing with EU clinical-supply clearance reduces reliance on third-party contract manufacturers for a technically demanding cell therapy process.

Strategic Risks & Vulnerabilities

1. Loss of Its Largest Partner: Bristol Myers Squibb terminated its roughly $150 million-upfront, multi-billion-dollar-potential collaboration with Century in December 2024 (effective March 2025), citing portfolio prioritization — removing Century's largest source of non-dilutive funding and a key validation signal.
2. Early-Stage Pipeline, No Approved Products: Every program is preclinical or early Phase 1/2; CNTY-813, the current top priority, is not expected to reach the clinic with initial human data until the second half of 2027 at the earliest.
3. Cash Runway and Dilution Risk: Century ended 2025 with $117.1 million in cash and investments, down from $220.1 million a year earlier, and needed a January 2026 private placement to extend its runway into the first quarter of 2029 — a reminder that further dilutive financing is likely before any product could reach the market.
4. Crowded, Well-Capitalized Competitive Field: Allogeneic cell therapy is one of the most actively pursued areas in biotech, with Fate Therapeutics, Allogene, Caribou, and Nkarta all racing toward similar goals, any of which could reach clinical or regulatory milestones first.

---

5. Financial Overview

---

6. Summary Conclusion

Century Therapeutics is a platform bet on allogeneic, iPSC-derived cell therapy's ability to solve the scalability and cost problems of patient-specific CAR-T treatment, built around its Allo-Evasion™ immune-evasion technology and the flexibility to produce NK cells, T cells, and beta islet cells from one engineered cell source. That platform thesis took a real hit when Bristol Myers Squibb exited its multi-billion-dollar-potential collaboration in late 2024, and Century's unusually low 2025 net loss is largely an artifact of recognizing termination-related BMS revenue rather than a sign of improving fundamentals.

With every program still preclinical or early-stage and cash now extended only into early 2029 via additional dilutive financing, Century's near-term trajectory depends on whether CNTY-101's updated autoimmune data in 2026 and CNTY-813's progress toward an IND can re-establish investor and partner confidence in the platform before the next capital raise is needed.